Copper chelation therapy in Wilson disease: an Australian guide

Wilson disease is an inherited disorder in which the body cannot properly transport and remove copper. Excess copper accumulates first in the liver and may later affect the brain, eyes, kidneys and other tissues. Without treatment, the condition can cause serious liver damage, movement disorders, mood changes and other neurological symptoms.

Copper chelation therapy remains a central treatment for many people with Wilson disease. These medicines bind excess copper so it can be eliminated, usually through urine. Treatment decisions require specialist oversight, regular blood and urine testing, and a long-term plan that accounts for liver health, symptoms, age, pregnancy and access to medicines.

How copper builds up in Wilson disease

Wilson disease is usually caused by disease-causing variants in the ATP7B gene. This gene helps liver cells package copper into bile and release it from the body. When its function is impaired, copper accumulates in the liver and may eventually enter the bloodstream and deposit in other organs.

Symptoms vary widely. A child or young adult may present with abnormal liver tests, hepatitis, fatigue or jaundice, while another person may develop tremor, poor coordination, speech changes, depression or difficulty swallowing. Kayser–Fleischer rings, caused by copper deposition around the cornea, can support the diagnosis but are not present in every patient.

Diagnosis commonly combines liver function tests, serum ceruloplasmin, serum copper, 24-hour urinary copper, eye examination, genetic testing and, in selected cases, a liver biopsy. Because no single test is definitive in every patient, assessment by a hepatologist, gastroenterologist or metabolic physician is important.

How chelation removes excess copper

Penicillamine has been used for decades and works by binding copper, increasing its urinary excretion. It can be effective for significant copper overload, although adverse effects may include rash, fever, kidney problems, changes in blood counts and autoimmune complications. Some people also experience worsening neurological symptoms after treatment begins.

Trientine is another copper-binding medicine that promotes urinary copper excretion. It is often considered when penicillamine is poorly tolerated or unsuitable. Different formulations and brands may have specific storage, administration and supply requirements, so patients should follow the instructions provided by their treating team and pharmacist.

Zinc salts are frequently used as maintenance therapy or in selected people with less advanced disease. Zinc reduces intestinal copper absorption rather than removing stored copper rapidly, and it must generally be taken away from food and other medicines. It is not a substitute for urgent chelation in severe copper overload or acute liver failure.

Starting treatment and managing risks

The initial treatment plan depends on whether Wilson disease is discovered through liver abnormalities, neurological symptoms, family screening or an acute presentation. People with severe liver failure may require urgent assessment at a transplant centre. In Australia, referral pathways may involve major hospitals in Sydney, Melbourne, Brisbane, Adelaide or Perth, depending on where the patient lives.

Chelators are usually introduced carefully, particularly when neurological symptoms are present. A sudden release of copper can aggravate tremor, dystonia or speech difficulties in some patients. Regular review helps clinicians adjust the dose and identify complications before they become serious.

Monitoring may include full blood counts, kidney function, liver enzymes, urinary copper and measures of non-ceruloplasmin-bound copper. Doctors may also assess neurological function, mood, nutrition and adherence. Treatment should not be stopped suddenly without medical advice, as copper can accumulate again and cause irreversible injury.

Living with long-term copper control

Most people require lifelong treatment, even when symptoms improve and laboratory results become stable. Adherence can be difficult when a person feels well, particularly because some medicines need to be taken several times a day or separated from meals. Written routines, pharmacy support and regular appointments can make the regimen more manageable.

Dietary advice is individualised. During the early phase of treatment, clinicians may recommend limiting foods exceptionally high in copper, such as shellfish, liver, nuts, chocolate and some mushrooms. Extremely restrictive diets can create nutritional problems, so a dietitian should help tailor advice rather than relying on general lists found online.

For Australians living far from specialist centres, telehealth can support follow-up, while local pathology services may perform routine tests. Someone travelling between regional Queensland, Western Australia or the Northern Territory may need a supply plan for medicines, pathology referrals and specialist communication. Medicare arrangements, private pharmacy availability and medicine costs can vary, making advance coordination valuable.

Research and specialist care

Applied bioinorganic chemistry continues to influence the development of treatments that control metal ions more selectively. Researchers are studying improved chelators, agents that alter copper distribution and approaches that target the underlying ATP7B-related defect. Tetrathiomolybdate-based therapies have attracted interest because they may bind copper and reduce its biological activity, although availability and approval depend on the medicine and jurisdiction.

Specialist care often involves a team that may include a hepatologist, neurologist, genetic counsellor, pharmacist, dietitian and transplant service. Family members may be offered screening because Wilson disease is inherited and early treatment can prevent organ damage before symptoms appear.

For patients in Australia, the treating specialist remains the best source of information about approved products, Pharmaceutical Benefits Scheme arrangements, pregnancy planning and interactions with other medicines. The Australian market may differ from European or North American sources, so imported products or online supplements should not be used as substitutes for prescribed therapy.

People diagnosed with Wilson disease should keep an up-to-date medicine list, attend scheduled monitoring and report new neurological symptoms, jaundice, swelling, unusual bruising or reduced urine promptly. Family screening and genetic counselling can also help identify relatives who may benefit from early assessment.

Reliable education supports safer treatment decisions. Explore the scientific and clinical work presented through the International Symposium on Applied Bioinorganic Chemistry, and use established Australian specialist services, hospital teams and pharmacists for individual medical guidance. Seek professional advice before changing a chelator, zinc regimen, diet or monitoring schedule.